4/10/2023 0 Comments Postal 2 share the pain torrent![]() ![]() The consolidated sales and operating income increased to '' 8,508 crores from '' 8,005 crores in the previous year showing a growth of 6%. Other Comprehensive income and other adjustments Profit Before Depreciation, Net Finance Cost, Exceptional Items & Tax The summary of Standalone (Company) and Consolidated (Company and its subsidiaries) operating results for the year and appropriation Leverage (Net Debt-to-EBITDA) reduced to 1.3x as of 31 st March, 2022 compared to 1.6x as of 31 st March, 2021.The Company has initiated cost optimization measures to counter the margin impact from US business. While branded businesses for the Company continue to contribute positively to the overall margins for the Company, US business was negative due to high double digit pricing pressure and lack of new product launches pending the USFDA re-inspection of the manufacturing facilities. During the year, Torrent registered EBITDA margins at 30.8% (PY 31.6%).The state-of-the-art Oral Oncology manufacturing facility in Gujarat, which will cater to both regulated and non-regulated markets, Torrent will continue its focus on key ROW markets to develop them as growth engines of the future.ħ.It shall continue to expand its market coverage through new launches, and expansion of its non-tender & OTC business. Torrent has taken initiatives to strengthen its cost and price competitiveness.Germany revenues were impacted due to muted market growth, normalization in channel inventory and increasing competition in some of the large volume tenders.1 Indian Pharmaceutical company in Germany. Torrent is ranked amongst top 3 players in 26 molecules.In 2021-22, Torrent has filed 5 ANDAs (PY 11) and launched 4 products.Torrent has already completed its CAPAs and submitted the closure report and it continues to await guidance from the USFDA on re-inspection. US revenues continued to be impacted due to high price erosion on the base portfolio coupled with lack of new launches pending re-inspection of its facilities.With high chronicity of its portfolio, Torrent will continue to focus on brand building, in-clinic effectiveness, new launches and foraying into new therapies.For 2021-22, Brazil registered strong growth of 18% with strong recovery of the market, market outperformance, performance of top brands and strengthening of Brazilian currency.1 Indian Pharmaceutical company in Brazil. Torrent continues to be ranked the no.Torrent will continue to strengthen in competitive position through focus on new launches, market expansion, field force productivity and brand building.Torrent is ranked 8 th in the IPM with 10 brands with sales of more than '' 100 crores. ![]() Field Force expansion during the year was around 20%. As at the year end, field force productivity is '' 9.2 lacs per month, an improvement of 10% over previous year.Non-exclusive licensing agreement to use the patents and know-how in relation to the compound nirmatrelvir with Medicine Patent Pool for manufacture and commercialisation of the generic version of PAXLOVID™ Voluntary licensing agreements for Baricitinib and Molnupiravir During the year, The Company entered into collaborations on COVID Drugs:.The Company outperformed the market with growth of 17% complemented by top brands and new launches. After muted 2020-21, the Indian Pharmaceutical Market (‘IPM’), witnessed a steady recovery throughout the year with growth of 15% including COVID portfolio and 11% excluding COVID portfolio.The Company has designed multi-fold strategy, with four core ESG pillars that will enable it to navigate its growth in a manner that maximizes stakeholders’ value, consistently and sustainably. During the year, the Company adopted a structured ESG framework & strategy, based on international ESG standards and frameworks. At Torrent, sustainability has been bedrock of doing business and has always been an integral part of growth and decision-making.While Germany performance was impacted mainly by market factors and competition intensity, US continues to be impacted due to lack of new product approvals which depends on the re-inspection of facilities and consequent clearance by USFDA. Our business in generic-generic focused markets mainly US and Germany witnessed de-growth during the year. Torrent’s business in Branded generic markets witnessed continued growth momentum backed by market recovery, performance of top brands and new launches. While the financial year witnessed gradual recovery trends across the markets, the recovery trends were impacted intermittently by second and third wave of pandemic.2021-22: Accelerating growth with Sustainability: Statement for the year ended 31 st March, 2022.ġ. The Directors have the pleasure of presenting the Forty Ninth Annual Report of your Company together with the Audited Financial ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |